ABBV

AbbVie

Halal Rating :
Comfortable
See Details
Last Price $164.96 Last updated:
Market Cap $360.1b
7D Change -17.31%
1 Year Change 19.29%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NYSE
Next Earnings Date Oct. 25, 2024

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $14.46b $10.63b - - 0.00% 0.00%
June 30, 2024 $14.46b $10.46b - - 0.00% 0.00%
March 31, 2024 $12.31b $9.51b - - 0.00% 0.00%

Company Impact

Help us evaluate AbbVie's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Justification for our Halal Rating

Contribute

Recent News & Updates